Consolidated Statement Of Profit Or Loss

SANTEN PHARMACEUTICAL CO.,LTD. - Filing #7254751

Concept 2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
Consolidated statement of profit or loss
Statement of profit or loss
Revenue
300,004,000,000 JPY
301,965,000,000 JPY
Cost of sales
128,977,000,000 JPY
123,256,000,000 JPY
Gross profit
171,027,000,000 JPY
178,709,000,000 JPY
Selling, general and administrative expenses
87,967,000,000 JPY
91,529,000,000 JPY
Other income
589,000,000 JPY
1,548,000,000 JPY
Other expenses
3,854,000,000 JPY
15,301,000,000 JPY
Operating profit (loss)
46,880,000,000 JPY
38,541,000,000 JPY
Finance income
4,002,000,000 JPY
1,572,000,000 JPY
Finance costs
2,716,000,000 JPY
2,664,000,000 JPY
Share of profit (loss) of investments accounted for using equity method
-685,000,000 JPY
-7,575,000,000 JPY
Profit (loss) before tax
47,481,000,000 JPY
29,874,000,000 JPY
Income tax expense
11,628,000,000 JPY
3,171,000,000 JPY
Profit (loss)
JPY
36,256,000,000 JPY
36,256,000,000 JPY
-403,000,000 JPY
35,853,000,000 JPY
26,642,000,000 JPY
26,642,000,000 JPY
26,703,000,000 JPY
JPY
60,000,000 JPY
Profit (loss) attributable to
Owners of parent
36,256,000,000 JPY
26,642,000,000 JPY
Non-controlling interests
-403,000,000 JPY
60,000,000 JPY
Earnings (loss) per share
Basic earnings (loss) per share
103.98
72.59
Diluted earnings (loss) per share
103.68
72.37

Talk to a Data Expert

Have a question? We'll get back to you promptly.